MO vs. PM: Which Tobacco Stock Has More Puff Left in 2025?

The article contrasts Altria (MO) and Philip Morris International (PM), noting Altria's U.S. focus, pricing power, and growth in 'on!' oral nicotine pouches, despite headwinds from declining cigarette volumes and illicit e-vapor. Philip Morris, with a global footprint, is driving strong momentum in its smoke-free portfolio, led by IQOS and ZYN, across 97 markets. While Altria offers value appeal at a 10.96x forward P/E for income investors, Philip Morris's higher 20.12x multiple reflects its aggressive pivot and global smoke-free traction. Ultimately, PM appears better positioned for long-term growth despite currency and regulatory challenges, compared to MO's more challenged growth path.

Analysis

The tobacco sector presents a strategic divergence between Altria Group (MO) and Philip Morris International (PM). Altria’s U.S.-focused strategy demonstrates resilience through significant pricing power, evidenced by a 10.8% net price realization in smokeable products and a 2.7% rise in adjusted operating income in Q1 2025. Its growth in smoke-free alternatives is primarily driven by the 'on!' oral nicotine pouch brand, which saw an 18% shipment increase. However, the company faces substantial headwinds from declining cigarette volumes, macroeconomic strain on its U.S. consumer base, and the proliferation of illicit e-vapor products, which now comprise over 60% of the market. Furthermore, its e-vapor ambitions have been hampered by the temporary withdrawal of its NJOY ACE product. In contrast, Philip Morris is executing an aggressive global pivot to its smoke-free portfolio, which now serves 41.5 million users across 97 markets. Growth is propelled by its IQOS heated tobacco system and the regained momentum of ZYN in the U.S. Despite this strong operational performance, PM's stock has declined 11.6% over the past month, likely reflecting investor concerns over currency volatility and increasing regulatory risks in key markets like the EU. This performance contrasts with Altria's 2.1% gain. Valuation metrics reflect these differing profiles: Altria trades at a modest 10.96x forward P/E, while Philip Morris commands a premium 20.12x multiple, indicating market expectations for higher long-term growth. Analyst sentiment, while rating both as a 'Hold', shows a slight upward revision in PM's 2025 EPS estimate to $7.50, while Altria's remains unchanged at $5.37, subtly reinforcing PM's stronger growth outlook.

Key Decisions for Investors

• Investors seeking long-term growth in the transitioning nicotine market should consider Philip Morris, whose global leadership in smoke-free products provides a structural advantage, but must accept a premium valuation and monitor currency and regulatory risks.
• Altria offers a value and income-focused proposition, supported by its domestic pricing power and a 10.96x P/E, making it suitable for investors prioritizing yield, though they must weigh the significant risks from secular cigarette volume declines and the unresolved illicit e-vapor market.
• Despite its recent 11.6% stock price drop, Philip Morris's underlying operational momentum in its smoke-free portfolio remains strong, suggesting the weakness may present a potential entry point for those confident it can navigate near-term currency and regulatory hurdles.
• Key catalysts for Altria's stock performance will be its ability to successfully re-launch its NJOY e-vapor products and any effective regulatory crackdown on the illicit disposable market, which are crucial for its long-term viability beyond traditional tobacco.